2-bromo-3-fluoro-6-methoxypyridine | 1161497-33-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-bromo-3-fluoro-6-methoxypyridine
• CAS: 1161497-33-1
• 化学式: C₆H₅BrFNO
• mdl: MFCD18257619
• 分子量: 206.014
• InChiKey: RSIDBBAZCOTLAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-3-fluoro-6-methoxypyridine 在 甲醇 、 sodium tetrahydroborate 、 氯化亚砜 、 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 4.17h， 生成 (2S,3R)-methyl 3-(2-(3-(chloromethyl)-4-(3-fluoro-6-methoxypyridin-2-yl)phenyl)chroman-7-yl)-3-cyclopropyl-2-methylpropanoate
  参考文献：
  名称：

  [EN] ANTIDIABETIC BICYCLIC COMPOUNDS
  [FR] COMPOSÉS BICYCLIQUES ANTIDIABÉTIQUES

  摘要：

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能对通过G蛋白偶联受体40介导的疾病的治疗、预防和抑制具有用处。本发明的化合物可能对2型糖尿病的治疗有用，以及对常与该疾病相关的疾病，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症的治疗有用。

  公开号：

  WO2016022742A1

文献信息

• Antidiabetic bicyclic compounds
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10968193B2

  公开（公告）日：2021-04-06

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新型化合物及其药学上可接受的盐类是G-蛋白偶联受体40（GPR40）的激动剂，可用于治疗、预防和抑制由G-蛋白偶联受体40介导的疾病。本发明的化合物可用于治疗 2 型糖尿病以及通常与这种疾病相关的病症，包括肥胖和脂质紊乱，如混合性或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症。
• ANTIDIABETIC BICYCLIC COMPOUNDS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3177287A1

  公开（公告）日：2017-06-14
• [EN] 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE UTILISÉS COMME MODULATEURS DES RÉCEPTEURS GABA DE TYPE A
  申请人：[en]UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED

  公开号：WO2022079432A1

  公开（公告）日：2022-04-21

  The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof, wherein X1, L1, R1, R2, R3, R4, Ring A, n and p are as described herein. The compounds of the present invention have affinity for α2- and/or α3-subunit-5 containing GABAAreceptors. The present invention further provides the manufacture of the compounds of formula (I), pharmaceutical compositions comprising the compounds and their use as medicaments for the treatment of diseases and disorders associated with α2- and/or α3-GABAAreceptors, including, for example anxiety disorders.
• ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Amygdala Neurosciences, Inc.

  公开号：US20230399299A1

  公开（公告）日：2023-12-14

  Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and/or anxiety disorder, each individually or concurrent.